MX2022004983A - Composiciones de profarmaco y metodos de tratamiento. - Google Patents

Composiciones de profarmaco y metodos de tratamiento.

Info

Publication number
MX2022004983A
MX2022004983A MX2022004983A MX2022004983A MX2022004983A MX 2022004983 A MX2022004983 A MX 2022004983A MX 2022004983 A MX2022004983 A MX 2022004983A MX 2022004983 A MX2022004983 A MX 2022004983A MX 2022004983 A MX2022004983 A MX 2022004983A
Authority
MX
Mexico
Prior art keywords
treatment
methods
prodrug compositions
prodrug
compositions
Prior art date
Application number
MX2022004983A
Other languages
English (en)
Inventor
Rajesh Kumar Kainthan
Alexander Mark Schobel
Stephen Paul Wargacki
Stephanie M Varjan
Malarvizhi Durai
Original Assignee
Aquestive Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aquestive Therapeutics Inc filed Critical Aquestive Therapeutics Inc
Publication of MX2022004983A publication Critical patent/MX2022004983A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a composiciones farmacéuticas que incluyen un profármaco de epinefrina.
MX2022004983A 2019-11-01 2020-10-30 Composiciones de profarmaco y metodos de tratamiento. MX2022004983A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962929737P 2019-11-01 2019-11-01
PCT/US2020/058357 WO2021087359A1 (en) 2019-11-01 2020-10-30 Prodrug compositions and methods of treatment

Publications (1)

Publication Number Publication Date
MX2022004983A true MX2022004983A (es) 2022-09-23

Family

ID=73476280

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022004983A MX2022004983A (es) 2019-11-01 2020-10-30 Composiciones de profarmaco y metodos de tratamiento.

Country Status (11)

Country Link
US (1) US20210128511A1 (es)
EP (1) EP4051235A1 (es)
JP (1) JP2022554293A (es)
KR (1) KR20220126286A (es)
CN (1) CN115003279A (es)
AU (1) AU2020373100A1 (es)
BR (1) BR112022008294A2 (es)
CA (1) CA3159382A1 (es)
IL (1) IL292487A (es)
MX (1) MX2022004983A (es)
WO (1) WO2021087359A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230134136A (ko) 2021-01-15 2023-09-20 어퀘스티브 테라퓨틱스, 아이엔씨. 전구약물 조성물 및 치료 방법
US20230130055A1 (en) * 2021-10-22 2023-04-27 Aquestive Therapeutics, Inc. Pharmaceutical compositions with enhanced stability profiles
WO2023076477A2 (en) * 2021-10-27 2023-05-04 Insignis Therapeutics, Inc. Orally disintegrating tablet for epinephrine prodrug formulations
CN114276264B (zh) * 2021-12-07 2022-12-16 华南农业大学 一种芬氟拉明半抗原、人工抗原、抗体及其制备方法和应用
CN114994198B (zh) * 2022-05-20 2023-02-28 上海市精神卫生中心（上海市心理咨询培训中心） 一种液相色谱质谱联用法同时定量检测78种神经精神类药物的方法
US20240016734A1 (en) * 2022-06-14 2024-01-18 Aquestive Therapeutics, Inc. Enhanced delivery epinephrine and prodrug compositions
CN115554237B (zh) * 2022-12-08 2023-09-12 山东则正医药技术有限公司 一种卢美哌隆原位凝胶长效注射剂及其制备方法和用途

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5429824A (en) 1992-12-15 1995-07-04 Eastman Kodak Company Use of tyloxapole as a nanoparticle stabilizer and dispersant
US5587143A (en) 1994-06-28 1996-12-24 Nanosystems L.L.C. Butylene oxide-ethylene oxide block copolymer surfactants as stabilizer coatings for nanoparticle compositions
US5569448A (en) 1995-01-24 1996-10-29 Nano Systems L.L.C. Sulfated nonionic block copolymer surfactants as stabilizer coatings for nanoparticle compositions
US5622938A (en) 1995-02-09 1997-04-22 Nano Systems L.L.C. Sugar base surfactant for nanocrystals
US5591456A (en) 1995-02-10 1997-01-07 Nanosystems L.L.C. Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer
US5580579A (en) 1995-02-15 1996-12-03 Nano Systems L.L.C. Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers
US5565188A (en) 1995-02-24 1996-10-15 Nanosystems L.L.C. Polyalkylene block copolymers as surface modifiers for nanoparticles
US6153223A (en) 1998-06-05 2000-11-28 Watson Pharmaceuticals, Inc. Stabilized pharmaceutical compositions
US6428814B1 (en) 1999-10-08 2002-08-06 Elan Pharma International Ltd. Bioadhesive nanoparticulate compositions having cationic surface stabilizers
US7071186B2 (en) 1999-06-15 2006-07-04 Bristol-Myers Squibb Pharma Co. Substituted heterocycle fused gamma-carbolines
IL145998A0 (en) 1999-06-15 2002-07-25 Du Pont Pharm Co Substituted heterocycle fused gamma-carbolines
US6713471B1 (en) 1999-06-15 2004-03-30 Bristol-Myers Squibb Pharma Company Substituted heterocycle fused gamma-carbolines
US8765167B2 (en) 2001-10-12 2014-07-01 Monosol Rx, Llc Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US7666337B2 (en) 2002-04-11 2010-02-23 Monosol Rx, Llc Polyethylene oxide-based films and drug delivery systems made therefrom
US7425292B2 (en) 2001-10-12 2008-09-16 Monosol Rx, Llc Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom
US7357891B2 (en) 2001-10-12 2008-04-15 Monosol Rx, Llc Process for making an ingestible film
US8603514B2 (en) 2002-04-11 2013-12-10 Monosol Rx, Llc Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
DK1471887T3 (da) 2002-02-04 2010-06-07 Elan Pharma Int Ltd Nanopartikelkompositioner der har lysozym som overfladestabiliseringsmiddel
GB0505420D0 (en) 2005-03-16 2005-04-20 Isogenica Ltd Stable ligand selection method
JP5567349B2 (ja) 2007-03-12 2014-08-06 イントラ−セルラー・セラピーズ・インコーポレイテッド 置換ヘテロ環縮合ガンマ−カルボリンの合成
CN102046175B (zh) 2008-03-12 2015-08-12 细胞内治疗公司 取代的杂环稠合的γ-咔啉固体
EP2320731A4 (en) 2008-05-27 2012-09-26 Intra Cellular Therapies Inc METHOD AND COMPOSITIONS FOR SLEEPING AND OTHER DISORDERS
MX339805B (es) 2010-04-22 2016-06-10 Intra-Cellular Therapies Inc Compuestos organicos.
MX2014012374A (es) 2012-04-14 2015-04-17 Intra Cellular Therapies Inc Compuestos organicos.
US9789071B2 (en) * 2012-06-27 2017-10-17 G2B Pharma, Inc. Intranasal formulation of epinephrine for the treatment of anaphylaxis
EP2968320B1 (en) 2013-03-15 2020-11-11 Intra-Cellular Therapies, Inc. Organic compounds
KR102495941B1 (ko) 2013-12-03 2023-02-06 인트라-셀룰라 써래피스, 인코퍼레이티드. 신규한 방법
RU2016143091A (ru) 2014-04-04 2018-05-08 Интра-Селлулар Терапиз, Инк. Органические соединения
WO2015154025A1 (en) 2014-04-04 2015-10-08 Intra-Cellular Therapies, Inc. Organic compounds
US10179776B2 (en) 2014-06-09 2019-01-15 Intra-Cellular Therapies, Inc. Compounds and methods of use to treat schizophrenia
EP3452024A1 (en) * 2016-05-05 2019-03-13 Aquestive Therapeutics, Inc. Pharmaceutical compositions with enhanced permeation
US20190022023A1 (en) * 2016-05-05 2019-01-24 Aquestive Therapeutics, Inc. Enhanced delivery epinephrine and prodrug compositions
JP7431724B2 (ja) * 2017-09-27 2024-02-15 アクエスティブ セラピューティクス インコーポレイテッド 増強された透過を有する医薬組成物
CN111465391A (zh) 2017-09-27 2020-07-28 阿奎斯蒂弗医疗股份有限公司 具有增强的递送的肾上腺素和前药的组合物

Also Published As

Publication number Publication date
CN115003279A (zh) 2022-09-02
JP2022554293A (ja) 2022-12-28
WO2021087359A1 (en) 2021-05-06
KR20220126286A (ko) 2022-09-15
EP4051235A1 (en) 2022-09-07
AU2020373100A1 (en) 2022-05-19
BR112022008294A2 (pt) 2022-07-26
IL292487A (en) 2022-06-01
CA3159382A1 (en) 2021-05-06
US20210128511A1 (en) 2021-05-06

Similar Documents

Publication Publication Date Title
MX2022004983A (es) Composiciones de profarmaco y metodos de tratamiento.
WO2018022668A3 (en) NEUROMODULATORY COMPOSITIONS AND ASSOCIATED METHODS OF TREATING CANCER
MX2020003939A (es) Inhibidores de mdm2 y metodos terapeuticos que utilizan los mismos.
MX2023008031A (es) Inhibidores de la cinasa 2 de control general no desrepresible (gcn2) y usos de los mismos.
PH12020551934A1 (en) Magl inhibitors
PH12019501097A1 (en) Magl inhibitors
WO2018067512A8 (en) SPIROCYCLIC COMPOUNDS
PH12019501102A1 (en) Magl inhibitors
WO2018234568A3 (en) HYDROXYNORKETAMINE FOR USE IN TREATING DEPRESSION
PH12020552214A1 (en) Ectonucleotidase inhibitors and methods of use thereof
PH12018502154A1 (en) Methods of treating ocular conditions
MX2020013808A (es) Antagonista de gremlina-1 para la prevencion y el tratamiento del cancer.
MX2020011756A (es) Compuesto farmaceutico, sales del mismo, formulaciones del mismo y metodos para hacer y usar el mismo.
JOP20180018A1 (ar) تركيبات صيدلية تتضمن مثبط jak
JOP20220168A1 (ar) طرق علاج الطحال
PH12021550883A1 (en) Crystalline salts of a plasma kallikrein inhibitor
MX2021016050A (es) Formulaciones transdermicas.
MX2019014024A (es) Tratamiento de los trastornos depresivos.
MX2020013389A (es) Composiciones de terlipresina y usos de las mismas.
MX2021006102A (es) Suministro mejorado de agentes grandes.
WO2018211324A8 (en) Prodrugs for the treatment of disease
MX2021012152A (es) Metodos para el tratamiento de beta-talasemia.
MX2021004396A (es) Metodos y composiciones para el tratamiento de la mucositis oral.
MX2017014301A (es) Composiciones y metodos para el tratamiento o prevencion de hipertension pulmonar.
MX2019008847A (es) Profarmacos de cisteamina.